Dynavax Technologies Community

NasdaqGS:DVAX Community

1 Narratives written by author
0 Comments on narratives written by author
12 Fair Values set on narratives written by author

Dynavax Technologies

AN

AnalystConsensusTarget

Consensus Narrative from 4 Analysts

Shingles Vaccine Development Will Unlock Multibillion-Dollar Market

Key Takeaways Growth in the hepatitis B vaccine sector and strategic moves in accessibility could drive future market share and revenue for Dynavax. Strategic partnerships and share repurchase plans may enhance market reach and shareholder value, reflecting management's confidence in future earnings.

US$24.25

FV

57.5% undervalued

17.32%

Revenue growth p.a.

0

0

11

4 days ago